Squarepoint
LUCD icon

Squarepoint’s Lucid Diagnostics LUCD Stock Holding History

Squarepoint’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Sell
115,022
-227,861
-66% -$290K ﹤0.01% 4027
2025
Q4 		$374K Buy
342,883
+325,493
+1,872% +$364K ﹤0.01% 3445
2025
Q3 		$17.6K Sell
17,390
-94,845
-85% -$104K ﹤0.01% 4292
2025
Q2 		$129K Buy
112,235
+81,713
+268% +$106K ﹤0.01% 4103
2025
Q1 		$45.5K Buy
+30,522
New +$36.6K ﹤0.01% 4356

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Squarepoint's LUCD Position: Q1 2026 in Review

Squarepoint reduced its Lucid Diagnostics (LUCD) stake by 66% in Q1 2026, selling an estimated $290K and leaving 115,022 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #4027.

Squarepoint first reported a position in LUCD in Q1 2025 and has held it in 5 quarters since. The position peaked at $374K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Squarepoint held 115,022 shares of Lucid Diagnostics worth $132K as of Q1 2026.
  • Squarepoint sold 227,861 Lucid Diagnostics shares in Q1 2026, an estimated $290K.
  • Lucid Diagnostics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4027 holding.
  • Squarepoint first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 5 quarters since.
  • Squarepoint's Lucid Diagnostics position peaked at $374K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.